ImmunityBio, Inc. — Director's Dealing 2023

May 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2023-05-12

Reporting Person: SOON-SHIONG PATRICK (Director, See remarks, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-12	Convertible Promissory Note	$2.28	P		Acquired	2023-12-31	Common Stock ()	Indirect

Footnotes

F1: On May 12, 2023, the conversion price of the convertible promissory note previously issued on March 31, 2023 was fixed at $2.28 per share and the lender has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's common stock at a price of $2.28 per share. Dollar amount shown reflects the aggregate principal and interest accrued as of May 12, 2023.

F2: Convertible Promissory Note held by Nant Capital, LLC, an investment vehicle of the reporting person.